PCR158 Patient Reported Outcomes (PRO) From Ongoing Phase 2 Registrational Trial of Repotrectinib in Patients With ROS1-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (TRIDENT-1)
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.2093
https://www.valueinhealthjournal.com/article/S1098-3015(22)04298-X/fulltext
Title :
PCR158 Patient Reported Outcomes (PRO) From Ongoing Phase 2 Registrational Trial of Repotrectinib in Patients With ROS1-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (TRIDENT-1)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)04298-X&doi=10.1016/j.jval.2022.09.2093
First page :
Section Title :
Open access? :
No
Section Order :
11650